Search Results
Beyond JAK2 Inhibitors: New targets and new agents
Beyond JAK2 Inhibitors: New Targets and New Agents
Combination Therapy with JAK2 inhibitors in MPN
Update on JAK2 Inhibitors by Srdan Verstovsek, MD
Debate: Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)? - Yes
Update on JAK2 Inhibitors by Srdan Verstovsek, MD
A Conversation with an MPN Specialist: Old and New JAK Inhibitors
Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis
Polycythemia Vera: JAK2 Inhibitor Patient Selection
Understanding the mechanisms of action of new agents: Implications for efficacy and safety
JAK2 inhibitor appears effective in myelofibrosis
Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera
